Page last updated: 2024-11-08

glycitin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycitin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

glycitin : A glycosyloxyisoflavone that is isoflavone substituted by a methoxy group at position 6, a hydroxy group at position 4' and a beta-D-glucopyranosyloxy group at position 7. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID187808
CHEBI ID80373
SCHEMBL ID62443
MeSH IDM0396243

Synonyms (37)

Synonym
AC-6047
BIDD:ER0468 ,
4',7-dihydroxy-6-methoxyisoflavone-7-d-glucoside
4h-1-benzopyran-4-one, 7-(beta-d-glucopyranosyloxy)-3-(4-hydroxyphenyl)-6-methoxy-
glycitin
40246-10-4
glycitein 7-o-glucoside
3-(4-hydroxyphenyl)-6-methoxy-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
3-(4-hydroxyphenyl)-6-methoxy-4-oxo-4h-chromen-7-yl beta-d-glucopyranoside
g2s44p62xc ,
glycitein 7-o-beta-glucoside
A825006
3-(4-hydroxyphenyl)-6-methoxy-7-[3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one
S3825
unii-g2s44p62xc
glycitein-7-beta-o-glucoside
AKOS015892761
glycitin (constituent of soy isoflavones) [dsc]
4h-1-benzopyran-4-one, 7-(.beta.-d-glucopyranosyloxy)-3-(4-hydroxyphenyl)-6-methoxy-
3-(4-hydroxyphenyl)-6-methoxy-4-oxo-4h-chromen-7-yl .beta.-d-glucopyranoside
glycitein 7-o-.beta.-glucoside
glycitin [usp-rs]
glycitein-7-.beta.-o-glucoside
SCHEMBL62443
CHEBI:80373
HY-N0012
DTXSID80193227
glycitein-7-b-o-glucoside
glycitein 7-o-b-glucoside
glycitin, united states pharmacopeia (usp) reference standard
3-(4-hydroxyphenyl)-6-methoxy-7-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)-4h-chromen-4-one
Q27149383
mfcd00800711
3-(4-hydroxyphenyl)-6-methoxy-7-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-4h-chromen-4-one
7-(?-d-glucopyranosyloxy)-3-(4-hydroxyphenyl)-6-methoxy-4h-1-benzopyran-4-one; glycitein 7-o-glucoside; glycitein 7-o-?-glucoside; glycitein-7-?-o-glucoside; glycitin
CCG-269194
4',7-dihydroxy 6-methoxyisoflavone 7-o-glucoside

Research Excerpts

Overview

Glycitin is a natural ingredient derived from the seeds of leguminous plants. It exhibits antioxidant, antiallergic, and anti-osteoporosis activities.

ExcerptReferenceRelevance
"Glycitin is a natural ingredient derived from the seeds of leguminous plants and may have potent anti-inflammation features."( Glycitin alleviates lipopolysaccharide-induced acute lung injury via inhibiting NF-κB and MAPKs pathway activation in mice.
Chen, Y; Guo, M; Guo, S; Jiang, K; Wang, Y; Yang, M, 2019
)
2.68
"Glycitin is a soy isoflavone that exhibits antioxidant, antiallergic, and anti-osteoporosis activities. "( Soy Isoflavone Glycitin (4'-Hydroxy-6-Methoxyisoflavone-7-D-Glucoside) Promotes Human Dermal Fibroblast Cell Proliferation and Migration via TGF-β Signaling.
Cho, M; Huh, JS; Kim, YM; Lim, Y, 2015
)
2.21

Bioavailability

ExcerptReferenceRelevance
"In order to improve the solubility and bioavailability of a soy isoflavone extract (IFE), inclusion complexes (IFE-beta-CD) of the isoflavone extract with beta-cyclodextrin (beta-CD) were prepared and studied for their solubility and bioavailability."( Enhanced bioavailability of soy isoflavones by complexation with beta-cyclodextrin in rats.
Cho, NS; Chung, CB; Hwang, YI; Kim, DC; Kim, KH; Kim, TH; Kim, YH; Lee, SH; Yu, HJ, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
methoxyisoflavoneMembers of the class of isoflavones with at least one methoxy substituent.
hydroxyisoflavoneMember of the class of isoflavones bearing at least one hydroxy group.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
7-hydroxyisoflavones 7-O-beta-D-glucosideA glycosyloxyisoflavone that is any 7-hydroxyisoflavone compound in which the 7-hydroxy group has been converted into its corresponding O-beta-D-glucoside.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (46.15)29.6817
2010's11 (42.31)24.3611
2020's3 (11.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.28 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.90%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (93.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]